ERBB2 and cancer: HR+/HER2− breast cancers have the best prognosis, while TN cancers have the worst prognosis, in terms of 4-year breast cancer specific survival.[1,2] Additionally, while HR−/HER2+ tumors are generally more aggressive, they have targeted therapies available that can improve survival outcomes.[3]